Health Catalyst, Inc.

NasdaqGS:HCAT Voorraadrapport

Marktkapitalisatie: US$494.7m

Health Catalyst Toekomstige groei

Future criteriumcontroles 1/6

Health Catalyst zal naar verwachting groeien in winst en omzet met respectievelijk 27.7% en 10.5% per jaar. De winst per aandeel zal naar verwachting groeien met 33.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 9.7% zijn.

Belangrijke informatie

27.7%

Groei van de winst

33.9%

Groei van de winst per aandeel

Healthcare Services winstgroei31.0%
Inkomstengroei10.5%
Toekomstig rendement op eigen vermogen9.7%
Dekking van analisten

Good

Laatst bijgewerkt21 Nov 2024

Recente toekomstige groei-updates

Health Catalyst, Inc. (NASDAQ:HCAT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12
Health Catalyst, Inc. (NASDAQ:HCAT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Health Catalyst: Still Optimistic On Achieving Adjusted EBITDA Targets

Sep 24

Health Catalyst, Inc.'s (NASDAQ:HCAT) Shares Lagging The Industry But So Is The Business

Jul 17
Health Catalyst, Inc.'s (NASDAQ:HCAT) Shares Lagging The Industry But So Is The Business

Health Catalyst: Stellar Earnings Growth Projected

Jun 26

Health Catalyst, Inc. (NASDAQ:HCAT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12
Health Catalyst, Inc. (NASDAQ:HCAT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Benign Growth For Health Catalyst, Inc. (NASDAQ:HCAT) Underpins Its Share Price

Apr 04
Benign Growth For Health Catalyst, Inc. (NASDAQ:HCAT) Underpins Its Share Price

Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible

Mar 09

Health Catalyst Looks To Slim Down As It Faces Industry Headwinds (Downgrade)

Feb 16

Is Health Catalyst (NASDAQ:HCAT) A Risky Investment?

Jan 27
Is Health Catalyst (NASDAQ:HCAT) A Risky Investment?

What Health Catalyst, Inc.'s (NASDAQ:HCAT) 25% Share Price Gain Is Not Telling You

Dec 24
What Health Catalyst, Inc.'s (NASDAQ:HCAT) 25% Share Price Gain Is Not Telling You

Is Health Catalyst, Inc. (NASDAQ:HCAT) Trading At A 47% Discount?

Dec 15
Is Health Catalyst, Inc. (NASDAQ:HCAT) Trading At A 47% Discount?

Is Health Catalyst (NASDAQ:HCAT) Weighed On By Its Debt Load?

Oct 24
Is Health Catalyst (NASDAQ:HCAT) Weighed On By Its Debt Load?

Subdued Growth No Barrier To Health Catalyst, Inc.'s (NASDAQ:HCAT) Price

Jul 31
Subdued Growth No Barrier To Health Catalyst, Inc.'s (NASDAQ:HCAT) Price

Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?

Jun 27
Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?

Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?

Feb 22
Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?

Health Catalyst, Inc. (NASDAQ:HCAT) Shares Could Be 22% Above Their Intrinsic Value Estimate

Dec 06
Health Catalyst, Inc. (NASDAQ:HCAT) Shares Could Be 22% Above Their Intrinsic Value Estimate

Is Health Catalyst (NASDAQ:HCAT) Using Debt In A Risky Way?

Nov 03
Is Health Catalyst (NASDAQ:HCAT) Using Debt In A Risky Way?

Health Catalyst: Looking For A Turnaround For This 'Bio Boom' Candidate

Oct 14

Health Catalyst names Kevin Freeman as Chief Growth Officer, Tarah Bryan as Chief Marketing Officer, Dave Ross as Chief Technology Officer

Sep 07

Winst- en omzetgroeiprognoses

NasdaqGS:HCAT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026380-39134810
12/31/2025342-48-62914
12/31/2024308-6191614
9/30/2024302-79-16-1N/A
6/30/2024299-86-17-4N/A
3/31/2024297-106-31-17N/A
12/31/2023296-118-47-33N/A
9/30/2023290-124-44-29N/A
6/30/2023285-147-61-44N/A
3/31/2023282-148-59-42N/A
12/31/2022276-137-53-35N/A
9/30/2022272-151-47-30N/A
6/30/2022265-145-40-24N/A
3/31/2022254-147-34-19N/A
12/31/2021242-153-42-23N/A
9/30/2021230-147-39-17N/A
6/30/2021216-135-36-17N/A
3/31/2021200-126-29-13N/A
12/31/2020189-115-37-26N/A
9/30/2020179-86-39-35N/A
6/30/2020171-99-41-36N/A
3/31/2020165-181-48-44N/A
12/31/2019155-241-37-32N/A
9/30/2019148-304-37-32N/A
6/30/2019141-282-37-33N/A
3/31/2019127-190-41-38N/A
12/31/2018113-114-43-40N/A
12/31/201773-59N/A-37N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat HCAT de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat HCAT de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat HCAT de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van HCAT ( 10.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van HCAT ( 10.5% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen HCAT zal naar verwachting over 3 jaar laag zijn ( 9.7 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y